Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies

This publication has 60 references indexed in Scilit:

• Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment
  Blood, 2002
• Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
  Proceedings of the National Academy of Sciences, 2002
• ZD1839 (IRESSA), an EGFR‐selective tyrosine kinase inhibitor, enhances taxane activity in bcl‐2 overexpressing, multidrug‐resistant MCF‐7 ADR human breast cancer cells
  International Journal of Cancer, 2002
• EGF receptor targeting in therapy-resistant human tumors
  Drug Resistance Updates, 2002
• Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.
  Endocrine-Related Cancer, 2001
• Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer
  Journal of Clinical Oncology, 2001
• Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents
  Drug Resistance Updates, 2001
• Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies
  JNCI Journal of the National Cancer Institute, 1993
• Efficacy of Antibodies to Epidermal Growth Factor Receptor Against KB Carcinoma In Vitro and in Nude Mice
  JNCI Journal of the National Cancer Institute, 1988
• The Mechanism of Acquired Resistance to Cisplatin by a Human Ovarian Cancer Cell Line
  Japanese Journal of Cancer Research, 1988